Apeloa Pharmaceutical Co.,Ltd (SHE:000739)
China · Delayed Price · Currency is CNY 19.37
-0.13 (-0.67%)
Oct 30, 2026, 3:04 PM CST
SHE:000739 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 8,799 | 9,728 | 11,957 | 11,440 | 10,506 | 8,910 |
Other Revenue | 55.48 | 55.48 | 65.35 | 33.92 | 39.1 | 32.44 |
| 8,854 | 9,784 | 12,022 | 11,474 | 10,545 | 8,943 | |
Revenue Growth | -15.64% | -18.62% | 4.77% | 8.81% | 17.92% | 13.49% |
Cost of Revenue | 6,421 | 7,298 | 9,225 | 8,621 | 8,075 | 6,579 |
Gross Profit | 2,434 | 2,486 | 2,796 | 2,853 | 2,470 | 2,364 |
Selling, General & Admin | 897.92 | 971.42 | 1,121 | 1,125 | 985.33 | 906.43 |
Research & Development | 573.37 | 611.17 | 641.47 | 624.87 | 532.92 | 446.22 |
Other Operating Expenses | 67.76 | 35.38 | 12.76 | 23.3 | 31.76 | 33.05 |
Operating Expenses | 1,567 | 1,608 | 1,785 | 1,775 | 1,563 | 1,405 |
Operating Income | 867.04 | 877.83 | 1,012 | 1,078 | 906.8 | 959.39 |
Interest Expense | -31.71 | -24.65 | -32.2 | -43.77 | -59.23 | -35.72 |
Interest & Investment Income | 83.77 | 131.78 | 92.17 | 113.47 | 75.83 | 165.7 |
Currency Exchange Gain (Loss) | -25.51 | -25.51 | 58.38 | 38.13 | 93.42 | -23.09 |
Other Non Operating Income (Expenses) | -81.99 | -1.82 | 2.18 | -23.85 | -5.38 | -3.58 |
EBT Excluding Unusual Items | 811.6 | 957.62 | 1,132 | 1,162 | 1,011 | 1,063 |
Gain (Loss) on Sale of Investments | 24.17 | - | -10.13 | -21.7 | -82.61 | -23.62 |
Gain (Loss) on Sale of Assets | 7.1 | 9.03 | 0.28 | 1.33 | 1.37 | 0.28 |
Asset Writedown | 17.47 | -5 | -8.37 | - | -4.67 | -7.95 |
Other Unusual Items | 104.35 | 104.55 | 89.22 | 63.23 | 86.52 | 82.67 |
Pretax Income | 964.68 | 1,066 | 1,203 | 1,205 | 1,012 | 1,114 |
Income Tax Expense | 161.62 | 175.52 | 172.44 | 149.34 | 22.89 | 158.53 |
Earnings From Continuing Operations | 803.06 | 890.68 | 1,031 | 1,055 | 989.17 | 955.55 |
Minority Interest in Earnings | 1.02 | -0 | 0.27 | 0.03 | 0 | - |
Net Income | 804.08 | 890.68 | 1,031 | 1,055 | 989.17 | 955.55 |
Net Income to Common | 804.08 | 890.68 | 1,031 | 1,055 | 989.17 | 955.55 |
Net Income Growth | -6.69% | -13.62% | -2.30% | 6.69% | 3.52% | 17.00% |
Shares Outstanding (Basic) | 1,154 | 1,153 | 1,163 | 1,169 | 1,174 | 1,179 |
Shares Outstanding (Diluted) | 1,154 | 1,153 | 1,163 | 1,169 | 1,174 | 1,179 |
Shares Change | -0.17% | -0.86% | -0.52% | -0.40% | -0.38% | -0.00% |
EPS (Basic) | 0.70 | 0.77 | 0.89 | 0.90 | 0.84 | 0.81 |
EPS (Diluted) | 0.70 | 0.77 | 0.89 | 0.90 | 0.84 | 0.81 |
EPS Growth | -6.54% | -12.87% | -1.78% | 7.12% | 3.91% | 17.00% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 678.9 | 833.99 | 748.01 | 400.9 | 817 | -90.18 |
Free Cash Flow Per Share | 0.59 | 0.72 | 0.64 | 0.34 | 0.70 | -0.08 |
Dividend Per Share | 0.377 | 0.586 | 0.356 | 0.317 | 0.297 | 0.285 |
Dividend Growth | -46.48% | 64.68% | 12.35% | 6.70% | 4.21% | 17.28% |
Gross Margin | 27.49% | 25.41% | 23.26% | 24.86% | 23.42% | 26.43% |
Operating Margin | 9.79% | 8.97% | 8.42% | 9.39% | 8.60% | 10.73% |
Profit Margin | 9.08% | 9.10% | 8.58% | 9.20% | 9.38% | 10.69% |
Free Cash Flow Margin | 7.67% | 8.52% | 6.22% | 3.49% | 7.75% | -1.01% |
EBITDA | 1,603 | 1,540 | 1,576 | 1,631 | 1,296 | 1,318 |
EBITDA Margin | 18.10% | 15.74% | 13.11% | 14.21% | 12.29% | 14.74% |
D&A For EBITDA | 735.69 | 662.17 | 564.15 | 553.06 | 389.43 | 358.64 |
EBIT | 867.04 | 877.83 | 1,012 | 1,078 | 906.8 | 959.39 |
EBIT Margin | 9.79% | 8.97% | 8.42% | 9.39% | 8.60% | 10.73% |
Effective Tax Rate | 16.75% | 16.46% | 14.33% | 12.40% | 2.26% | 14.23% |
Revenue as Reported | 8,854 | 9,784 | 12,022 | 11,474 | 10,545 | 8,943 |
Advertising Expenses | - | 9.35 | 11.29 | 9.67 | 1.61 | 1.86 |